- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04137068
Sedentary Behavior, Cardiovascular Function, and Sleep (PACE)
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
PRIMARY OBJECTIVES:
1. To test the hypothesis that two weeks of sedentary behavior will progressively impair vascular endothelial function.
2: To test the hypothesis that increasing sedentary behavior will decrease total sleep duration and sleep efficiency.
3: To test the hypothesis that two-weeks of sedentary behavior will progressively increase 24-h blood pressure and reduce nocturnal blood pressure dipping.
OUTLINE:
After a baseline period, participants will become more inactive and also come in for 4-h uninterrupted sitting visits. Cardiovascular, activity, and sleep measures will be taken throughout.
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Oregon
-
Portland, Oregon, Forente stater, 97239
- Rekruttering
- Oregon Institute of Occupational Health Sciences
-
Ta kontakt med:
- Saurabh Thosar, Dr.
- Telefonnummer: 503-494-2064
- E-post: thosar@ohsu.edu
-
Hovedetterforsker:
- Saurabh Thosar, Dr.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Ages 20-80y
- Lean and overweight (BMI 18.5-40 kg/m2)
- No acute, chronic, or debilitating medical conditions
- No prescription/non-prescription medications or drugs of abuse
- Limited weight training or intense exercise (swimming, CrossFit)
- Non-smoker
- Average level of daily physical activity (8,000-12,499 steps/day)
- Persons who fit all the above criteria and are suitable based on a medical history and health habits questionnaire, sleep profiling questionnaire, and electrocardiogram and clinical biochemical screening tests of blood and urine may be eligible to participate.
Exclusion Criteria:
- Persons with any acute, chronic, or debilitating medical condition except pre-hypertension and/or mild to moderate sleep apnea will be excluded.
- Persons with any symptoms of acute or active illness (e.g. fever, leukocytosis) will be excluded.
- Persons with a history of severe psychiatric illness or psychiatric disorders will be excluded.
- Persons with a history of regular night/or rotating shift work, or who have traveled more than three time zones during the one month prior to the study will be excluded.
- Pregnant persons, decisionally impaired adults, and prisoners will be excluded.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Annen: Sedentary to Active
Participants will visit the research laboratory for baseline measurements at visit 1 after wearing a pedometer for one week and maintaining their typical level of physical activity.
After the baseline visit, participants will reduce their step count by more than half for two weeks.
Participants will visit the laboratory once every week during the 2 week interventional period for a total of 3 visits.
|
Participants reduce their activity level to <5,000 steps/day and <50 % of baseline steps.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Endothelial Function
Tidsramme: 3 weeks
|
Investigators will measure endothelial function as flow-mediated dilation at baseline, and each hour of the 3-hour sitting trials.
|
3 weeks
|
|
Oxidative stress
Tidsramme: 3 weeks
|
Oxidative stress will be measured using malondialdehyde adducts (MDA) from Ethylenediaminetetraacetic acid (EDTA) plasma.
|
3 weeks
|
|
Endothelin-1
Tidsramme: 3 weeks
|
Endothelin 1 (ET-1) will be measured from Ethylenediaminetetraacetic acid (EDTA) plasma.
|
3 weeks
|
|
Heart rate
Tidsramme: 3 weeks
|
During the weekly trials, heart rate will be measured as beats per minute while participants are in a seated position during the prolonged sitting period.
|
3 weeks
|
|
Blood pressure
Tidsramme: 3 weeks
|
During the weekly trials, blood pressure will be measured as systolic over diastolic in a seated position in the dominant arm
|
3 weeks
|
|
24-hour BP measurement
Tidsramme: 3 weeks
|
Investigators will measure 24-hour ambulatory blood pressure monitoring (AMBP, Spacelabs, Inc) at baseline and for 24-h before each in-lab visit.
|
3 weeks
|
|
Sleep duration
Tidsramme: 3 weeks
|
Sleep duration will be scored from the ActiGraph and correlated with the sleep and activity diary.
|
3 weeks
|
|
Sleep efficiency
Tidsramme: 3 weeks
|
Sleep efficiency will be scored from the ActiGraph and correlated with the sleep and activity diary.
|
3 weeks
|
|
Activity
Tidsramme: 3 weeks
|
Activity will be scored from the ActiGraph and correlated with the sleep and activity diary.
|
3 weeks
|
|
Activity Perception
Tidsramme: 3 weeks
|
Activity perception will be measured before each prolonged sitting trial using an Activity Perception questionnaire (Perception of Current Activity Questionnaire).
The questionnaire has 7 questions with answers ranging from 1 to 5. The range of scores is from 7 to 35, with 7 suggesting a strong negative perception of current activity, and 35 suggesting a strong positive perception of current activity.
|
3 weeks
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Saurabh Thosar, Dr., Oregon Institute of Occupational Health Sciences
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- STUDY00020458
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .